David V Goeddel
CIK 1182464 · last filed 2025-05-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RAPT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1 LETTERMAN DR, BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TNYA | Director | 4,985,570 | $0.41 | $2.04M | $64.56M | 12 | 2025-05-30 |
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Director | 0 | $1.54 | $0 | $97.10M | 64 | 2024-04-08 |
| RAPT Therapeutics, Inc. (RAPT) Delisted | Director | 175,271 | $58.01 | $10.17M | $144.13M | 3 | 2022-05-25 |
| ORIC | 10%+ Owner | 4,616,666 | $8.96 | $41.34M | $0 | 1 | 2020-04-28 |
| Gritstone bio, Inc. (GRTS) Delisted | 3,102,934 | $0.03 | $99.9K | $0 | 1 | 2018-10-02 |
Recent Filings · Page 5 of 9
81 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-10 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-09-03 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +384,534 | $6.79M | EDGAR |
| 2020-08-25 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +110,670 | $1.99M | EDGAR |
| 2020-07-30 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +24,630 | $443.1K | EDGAR |
| 2020-05-22 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-28 | ORIC | Conv (C) | +14,079,543 | $0 | EDGAR |
| 2020-04-09 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +112,602 | $1.68M | EDGAR |
| 2020-04-07 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +138,315 | $1.96M | EDGAR |
| 2020-04-02 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +250,984 | $3.11M | EDGAR |
| 2020-03-25 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +301,180 | $3.58M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.